Our Story
In 2019, we launched our firm by focusing on the entrepreneurial community at Caltech. There we have found core science breakthroughs, deep tech innovation and a highly supportive environment for a new generation of founders.
In our first four years, we have invested in over 30 companies, forming our initial portfolio of category creating companies that leverage proprietary IP, AI, machine learning and other advanced technologies to move to market faster and more efficiently than ever.
Our Investment Model
From sourcing to support, our model is tailored to the needs of high-potential science-driven companies. We connect with founders in their early days of developing the company. We get to know them. They get to know us. Our investments are at the early stages and we're often the first venture investors. After investing, we support to help our companies attract customers, partners and new investors.
Connect
Develop deal flow in high quality scientific communities underserved by venture capital.
Invest
Deploy capital at early stage human and planetary health companies enabled by AI and ML.
Support
Serve founders and teams with non-science value add including fundraising, marketing, hiring and strategy.
$90M
AUM
Three funds to date: Fund One ($25M), Fund Two ($35M) and in early 2024, we closed our first Opportunity Fund at $15M. We also offered additional SPVs for breakout companies.
30+
Portfolio companies
We've invested in more than 30 companies at pre-seed, seed, Series A and Series B rounds. Deep tech that leverages computer science is our core thesis.
100+
Co-investors
Our companies continually attract co-investors from venture and corporate capital. We also regularly provide co-investment opportunities as companies grow and offer new value.
Convergent science yields new kinds of companies.
Advanced computing power is driving a revolution in higher precision, cross-discipline innovation that moves more efficiently from the lab to the field. We're committed investors for companies leading this change.
Read our article on deep tech fundraising
Convergent science yields new kinds of companies.
Advanced computing power is driving a revolution in higher precision, cross-discipline innovation that moves more efficiently from the lab to the field. We're committed investors for companies leading this change.
Read our article on deep tech fundraising
Iambic Therapeutics has created a disruptive platform for small-molecule drug discovery by harnessing leadership in physics-informed AI and tightly integrating AI-driven design and experimental execution.
StrokeDx is transforming stroke diagnosis with non-invasive, non-radiating portable imaging technology.
Hydrosat uses satellite imagery to provide geospatial intelligence for food security, public safety, and the environment.
Captura is a revolutionary system for capturing carbon dioxide from ocean water at scale.
Founder Sessions
Founder Sessions is our content series that sheds light on the origin stories of our portfolio company founders and leaders. These talks aim to educate and inspire our community.
News
We regularly post content and news from our portfolio companies and the Freeflow team.
